Abstract
•Transcatheter edge-to-edge repair (TEER) has now become the standard treatment option for patients with moderate to severe or severe symptomatic functional mitral regurgitation (MR) despite the guideline-directed medical therapy.•The MitraClip (Abbott Vascular, Santa Clara, California) is the only TEER system currently approved by the Food and Drug Administration for the treatment of functional MR.•This study has demonstrated the initial safety and efficacy of a new TEER device (Clip2Edge system, IasoCardiac Medical Technology Co, Ltd, Shanghai, China) for treating functional MR patients who remain symptomatic despite guideline-directed medical therapy.•This device may provide an additional treatment option for this patient population.